- Home
- / OptiNose
OptiNose
Stock Price
$1.5
2023-12-05
Market Capitalization
$164 M
2023-12-05
Revenue
$76.3 M
FY, 2022
OptiNose Summary
Company Summary
- Overview
- OptiNose develops nasal drug delivery technologies and combination drug-device therapies. It offers liquid delivery and powder delivery devices based on Bi-Directional Exhalation Delivery Systems (EDS). The company focuses on the treatment of chronic rhinosinusitis, nasal polyps, and chronic sinusitis.
- Type
- Public
- Status
- Active
- Founded
- 2000
- HQ
- Morrisville, PA, US | view all locations
- Website
- https://www.optinose.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Paul Spence, Chief Commercial Officer
Mike Marino, Chief Legal Officer
Ramona Lloyd, Senior Vice President, Regulatory & Quality
Operating MetricsView all
Patents Pending (US)
35
Jun, 2017
Trademarks (US)
3
Jun, 2017
Patents (US)
43
Jun, 2017
LocationsView all
3 locations detected
Morrisville, PA HQ
United States
1020 Stony Hill Rd #300
Oslo, Oslo
Norway
Gaustadalléen 21
Swindon, England
United Kingdom
Berkeley House, Hunts Rise
OptiNose Financials
Summary Financials
- Revenue (Q3, 2023)
- $19.8M
- Gross profit (Q3, 2023)
- $17.6M
- Net income (Q3, 2023)
- ($9.3M)
- Cash (Q3, 2023)
- $66.8M
- EBIT (Q3, 2023)
- ($1.7M)
- Enterprise value
- $226.9M